isabelle ray coquard

professor

France

Research Interests

Explore related searches

Professors in France Professors in Cancer Biology Cancer Biology professors in France

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Isabelle Ray Coquard is affiliated with the Centre Leon Berard in France. Her research primarily focuses on gynecological oncology, particularly in the areas of clinical trials, treatment outcomes for ovarian cancer, and the use of maintenance therapies such as PARP inhibitors. Professor Coquard has contributed to significant studies, including the GINECO trial for advanced endometrial cancer and the GANNET53 trial for platinum-resistant ovarian cancer.

Articles (28)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (16)

François Bertucci

Aix-Marseille University

FRANCE

isabelle ray coquard

Research Interests

Explore related searches

Contact this professor

About

Articles (28)

Pan-Asia adapted ESMO Clinical Practice Guideline for the management of patients with newly diagnosed and relapsed epithelial ovarian cancer

Quantité tissulaire optimale pour études ancillaires moléculaires des essais cliniques multicentriques en oncologie gynécologique : expérience du groupe de pathologistes en recherche translationnelle du GINECO

Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial

GANNET53 Part II: A European Phase I/II Trial of the HSP90 Inhibitor Ganetespib in High-Grade Platinum-Resistant Ovarian Cancer—A Study of the GANNET53 Consortium

Characterization and treatment outcomes of malignant histiocytoses in a retrospective series of 141 cases in France

PARP inhibitors as maintenance therapy in ovarian cancer after platinum-sensitive recurrence: real-world experience from the Unicancer network

Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician’s choice in advanced/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitors

Controversies in the organization and structure of management for rare tumors

The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial

Ovarian clear cell carcinoma: open questions on the management and treatment algorithm

Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer

Cancers de l’ovaire. Des nouvelles molécules pour chaque type histologique ou moléculaire, une avancée vers plus de guérison ?

Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial

Gene expression markers in peripheral blood and outcome in patients with platinum‐resistant ovarian cancer: A study of the European GANNET53 consortium

Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial

Management of patients with rare adult solid cancers: objectives and evaluation of European reference networks (ERN) EURACAN

Low-grade uterine Leiomyosarcoma is highly sensitive to hormonal treatment.

Evolving treatment paradigms in metastatic or recurrent low-grade endometrial cancer: When is hormonal-based therapy the preferred option?

Efficacy and Safety of Adjuvant Radiotherapy in Re-excised Soft-tissue Sarcoma After Unplanned Resection

Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort

Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775

Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation

Splenectomy in epithelial ovarian cancer surgery

Efficacy of chemotherapy according toBRCAstatus in patients with high-grade serous ovarian carcinoma at first platinum-sensitive relapse

Immune Environment and Immunotherapy in Endometrial Carcinoma and Cervical Tumors

CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data

The promise of combining CDK4/6 inhibition with hormonal therapy in the first-line treatment setting for metastatic or recurrent endometrial adenocarcinoma

Gestational choriocarcinoma

Collaborators (16)

François Bertucci

Ioana Braicu

Simon Schallenberg

Jalid Sehouli

Jonathan Ledermann

Christophe Le Tourneau

ANA OAKNIN

Caroline Kelly

David S. Miller

Manuel Rodrigues

Benoit You

Mansoor Mirza

Anthony Gonçalves

Maud Kamal

Jean-Yves Blay

Antonio González-Martín

Make your next move.